In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Prostatype Genomics AB's net current asset value per share for the quarter that ended in Dec. 2025 was kr-0.09.
The historical rank and industry rank for Prostatype Genomics AB's Net Current Asset Value or its related term are showing as below:
During the past 7 years, the highest Price-to-Net-Current-Asset-Value Ratio of Prostatype Genomics AB was 22.88. The lowest was 5.17. And the median was 10.38.
OSTO:PROGEN's Price-to-Net-Current-Asset-Value is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 3.8 * Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
Prostatype Genomics AB (OSTO:PROGEN) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Prostatype Genomics AB Net Current Asset Value Related Terms
Prostatype Genomics AB Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Prostatype Genomics AB's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prostatype Genomics AB Net Current Asset Value Chart
OSTO:PROGEN vs TMO, DHR, IDXX: Net Current Asset Value Comparison
For the Diagnostics & Research subindustry, Prostatype Genomics AB's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prostatype Genomics AB Price-to-Net-Current-Asset-Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Prostatype Genomics AB's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of kr-0.09 mean?
Prostatype Genomics AB (OSTO:PROGEN) has a Net Current Asset Value of kr-0.09 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Prostatype Genomics AB and its competitors. Over the past decade, Prostatype Genomics AB's Net Current Asset Value has ranged from 5.17 to 22.88. According to the industry distribution chart, Prostatype Genomics AB ranks #999999 out of 100 companies in the Medical Diagnostics & Research industry.
Is Prostatype Genomics AB's Net Current Asset Value too high?
Prostatype Genomics AB's current Net Current Asset Value is kr-0.09. Over the past 10 years, this metric has ranged from a low of 5.17 to a high of 22.88. Based on the distribution chart, Prostatype Genomics AB ranks #999999 out of 100 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Prostatype Genomics AB has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's Net Current Asset Value compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Prostatype Genomics AB ranks #999999 out of 100 companies for Net Current Asset Value. This places Prostatype Genomics AB in the lower half of its industry. The industry median Net Current Asset Value is 3.80. Historically, Prostatype Genomics AB's own Net Current Asset Value has ranged from 5.17 to 22.88 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Diagnostics & Research company?
The median Net Current Asset Value among Medical Diagnostics & Research companies is 3.80, based on 100 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Prostatype Genomics AB and its competitors. For the Medical Diagnostics & Research industry, the median Net Current Asset Value is 3.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prostatype Genomics AB's current Net Current Asset Value is kr-0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.04, compared to a current price of kr0.37 — trading 830% above its estimated fair value. The current Net Current Asset Value is kr-0.09. Prostatype Genomics AB's overall GF Score™ is 25/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current Net Current Asset Value is kr-0.09 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued.
The current stock price of kr0.37 is trading 830% above its estimated GF Value™ of kr0.04.
GuruFocus considers Prostatype Genomics AB to be Significantly Overvalued.
Key valuation signals for OSTO:PROGEN:
Net Current Asset Value: kr-0.09
GF Value™: kr0.04 vs. price of kr0.37 (830% above fair value)
No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
25GF Score
Get the complete analysis for OSTO:PROGEN
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:PROGEN has been successfully added to your 
